|
NO2694640T3
(me)
*
|
2011-04-15 |
2018-03-17 |
|
|
|
WO2013009701A2
(en)
|
2011-07-08 |
2013-01-17 |
The University Of North Carolina At Chapel Hill |
Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
|
|
SG11201507255QA
(en)
|
2013-03-14 |
2015-10-29 |
Newlink Genetics Corp |
Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization
|
|
CN105209449B
(zh)
|
2013-03-14 |
2019-02-01 |
ćșæćŸ·ć€«ć¶èŻç§äșșæéć
Źćž |
çŹć°żæ°šé
žéćŸçæć¶ć
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
CN103382187B
(zh)
*
|
2013-08-06 |
2015-06-03 |
俥ćźçç©ć»èŻïŒäžæ”·ïŒæéć
Źćž |
äžç§3-æ°Ż-7(5)-æșŽèŻćč¶ćŒæ¶ćçćææčæł
|
|
ES2857848T3
(es)
|
2013-12-24 |
2021-09-29 |
Bristol Myers Squibb Co |
Compuestos tricĂclicos como agentes antineoplĂĄsicos
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
PT3151921T
(pt)
|
2014-06-06 |
2019-11-21 |
Bristol Myers Squibb Co |
Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizaçÔes dos mesmos
|
|
SG10201804868PA
(en)
*
|
2014-09-05 |
2018-07-30 |
Merck Patent Gmbh |
Compounds for the inhibition of indoleamine-2,3-dioxygenase
|
|
GB201417369D0
(en)
*
|
2014-10-01 |
2014-11-12 |
Redx Pharma Ltd |
Compounds
|
|
GB201418300D0
(en)
*
|
2014-10-15 |
2014-11-26 |
Redx Pharma Ltd |
Compounds
|
|
JP6882978B2
(ja)
|
2014-10-29 |
2021-06-02 |
ăă€ăčăŻă«ăąăŒă«ăăŁăŒă»ăȘăăăă |
ïŒïœïŒâïœïœïœă«çčç°çăȘäșç°æ§ăăăăăȘăŹăłă
|
|
MY189836A
(en)
|
2014-11-21 |
2022-03-11 |
Bristol Myers Squibb Co |
Antibodies against cd73 and uses thereof
|
|
US10525035B2
(en)
|
2014-12-18 |
2020-01-07 |
Lankenau Institute For Medical Research |
Methods and compositions for the treatment of retinopathy and other ocular diseases
|
|
TW201630907A
(zh)
|
2014-12-22 |
2016-09-01 |
ćż
æČ»ćŠ„çŸé
ćČè°·æŻć
Źćž |
ÎČïŒČæźæć
|
|
CN107207594B
(zh)
|
2014-12-23 |
2019-05-07 |
çŸæ¶çŸæœèŽ”ćźć
Źćž |
éćŻčtigitçæäœ
|
|
US10983128B2
(en)
|
2015-02-05 |
2021-04-20 |
Bristol-Myers Squibb Company |
CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
|
|
CN105884828A
(zh)
*
|
2015-02-16 |
2016-08-24 |
äžæ”·èżȘèŻșć»èŻç§ææéć
Źćž |
ć€çŻććç©ăć
¶èŻç©ç»ćç©ććșçš
|
|
ES2789331T3
(es)
|
2015-03-02 |
2020-10-26 |
Rigel Pharmaceuticals Inc |
Inhibidores de TGF-beta
|
|
KR20170134980A
(ko)
|
2015-04-03 |
2017-12-07 |
ëžëŠŹì€íš-ë§ìŽìŽì€ ì€í
컎íŒë |
ìì ìčëŁë„Œ ìí ìžëìëŻŒ-2,3-ëì„ìêČëì ì ì”ì ì
|
|
TW201642897A
(zh)
|
2015-04-08 |
2016-12-16 |
 æçç©ç§ææéć
Źćž |
ïœ
ïœïŒç”ććæČ»ç
|
|
JP6806342B2
(ja)
*
|
2015-04-10 |
2021-01-06 |
ăă€ăžăŒăł ăȘăăăă |
ă€ăłăăŒă«ăąăăłăšăăŠăźæ°èŠïŒćăŻïŒâçœźæă€ăăăŸïŒ»ïŒïŒïŒâïœïŒœăăȘăžăłéĄăćăłïŒćăŻăăȘăăăăĄăłïŒïŒïŒâăžăȘăă·ăČăăŒăŒ
|
|
JP2018511647A
(ja)
|
2015-04-12 |
2018-04-26 |
ăăłăžă§ăŠ ă€ăăČăŒă ăăĄăŒă ă«ăłăăăŒ ăȘăăăăïœïœïœïœïœïœïœ ïœïœïœïœïœïœïœ
ïœïœïœïœïœ ïŒŁïœïŒïŒïŒŹïœïœïŒ |
ïœïœé»ćźłć€ăšïœïœïœé»ćźłć€ăšăăŠăźè€çŽ ç°ććç©
|
|
BR112017020952A2
(pt)
|
2015-04-13 |
2018-07-10 |
Five Prime Therapeutics Inc |
método de tratamento de cùncer, composição e uso da composição
|
|
JP6801159B2
(ja)
*
|
2015-04-21 |
2020-12-16 |
ăžăšăłăč ăăłă«ă€ ăĄăă€ă·ăłă«ăłăăăŒ ăȘăăăăïŒȘïœïœïœïœïœïœ ïœ
ïœïœïœïœïœ ïŒïœ
ïœïœïœïœïœïœ
ïŒŁïœïŒïŒïŒŹïœïœïŒ |
ă€ăăăŸă€ăœă€ăłăăŒă«èȘć°äœăăăźèŁœé æčæłćăłăăźć»èŹçšé
|
|
EP3294736B1
(en)
|
2015-05-11 |
2020-07-22 |
Bristol-Myers Squibb Company |
Tricyclic compounds as anticancer agents
|
|
EP3307740B1
(en)
|
2015-05-12 |
2019-12-18 |
Bristol-Myers Squibb Company |
5h-pyrido[3,2-b]indole compounds as anticancer agents
|
|
US9725449B2
(en)
|
2015-05-12 |
2017-08-08 |
Bristol-Myers Squibb Company |
Tricyclic compounds as anticancer agents
|
|
TN2019000101A1
(en)
|
2015-05-29 |
2020-07-15 |
Bristol Myers Squibb Co |
Antibodies against ox40 and uses thereof.
|
|
GB2548542A
(en)
*
|
2015-06-16 |
2017-09-27 |
Redx Pharma Plc |
Compounds
|
|
CN106256830B
(zh)
*
|
2015-06-18 |
2019-03-08 |
æéœæ”·ćèŻäžæéć
Źćž |
äžç§æ°ä»Łçidoæć¶ććć
¶ć¶ć€æčæłćçšé
|
|
AU2016285920A1
(en)
|
2015-06-29 |
2018-02-01 |
Bristol-Myers Squibb Company |
Antibodies to CD40 with enhanced agonist activity
|
|
CN105037371A
(zh)
*
|
2015-06-30 |
2015-11-11 |
è„żćć€§ćŠ |
äžç§æ°ä»ŁçćČćèș-2,3-ćć æ°§é
¶æć¶ć
|
|
GB201511790D0
(en)
|
2015-07-06 |
2015-08-19 |
Iomet Pharma Ltd |
Pharmaceutical compound
|
|
IL274572B2
(en)
|
2015-07-16 |
2024-01-01 |
Biolinerx Ltd |
Compositions and methods for treating cancer
|
|
EP3954369B1
(en)
|
2015-07-24 |
2025-08-20 |
Lumos Pharma, Inc. |
Salts and prodrugs of 1-methyl-d-tryptophan
|
|
CN108137597A
(zh)
|
2015-07-28 |
2018-06-08 |
çŸæ¶çŸæœèŽ”ćźć
Źćž |
TGFÎČćäœæźæć
|
|
EP3337476A4
(en)
|
2015-08-19 |
2019-09-04 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
WO2017035118A1
(en)
|
2015-08-25 |
2017-03-02 |
Bristol-Myers Squibb Company |
Tgf beta receptor antagonists
|
|
CN106478634B
(zh)
*
|
2015-09-01 |
2020-05-22 |
ć°ćć»èŻç§æ(æ±è„ż)æéć
Źćž |
çš ććȘćććç©ăć
¶ć¶ć€æčæłăèŻç©ç»ćç©ćçšé
|
|
WO2017075341A1
(en)
*
|
2015-10-29 |
2017-05-04 |
Scifluor Life Sciences, Inc. |
Fused imidazole derivatives as ido/tdo inhibitors
|
|
AU2016350701B2
(en)
|
2015-11-02 |
2021-08-19 |
Five Prime Therapeutics, Inc. |
CD80 extracellular domain polypeptides and their use in cancer treatment
|
|
WO2017080934A1
(en)
*
|
2015-11-09 |
2017-05-18 |
F. Hoffmann-La Roche Ag |
Screening assay to identify id01 and/or tdo modulators
|
|
BR112018010172A2
(pt)
|
2015-11-19 |
2018-11-21 |
Bristol Myers Squibb Co |
anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos
|
|
US20170145103A1
(en)
|
2015-11-23 |
2017-05-25 |
Five Prime Therapeutics, Inc. |
Predicting response to cancer treatment with fgfr2 inhibitors
|
|
KR102738306B1
(ko)
|
2015-12-15 |
2024-12-03 |
ëžëŠŹì€íš-ë§ìŽìŽì€ ì€í
컎íŒë |
Cxcr4 ìì©ìČŽ êžžíì
|
|
TW201730190A
(zh)
*
|
2015-12-24 |
2017-09-01 |
Genentech Inc |
ïœïœïŒæć¶ć
|
|
CN107056785B
(zh)
*
|
2016-01-02 |
2021-06-22 |
æć·è±ćć»èŻç§ææéć
Źćž |
äœäžșidoćtdoæć¶ćçæçŻććç©
|
|
AU2017215424A1
(en)
*
|
2016-02-02 |
2018-08-09 |
Emcure Pharmaceuticals Limited |
Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer
|
|
CN108884104B
(zh)
*
|
2016-02-19 |
2021-01-15 |
æŁć€§ć€©æŽèŻäžéćąèĄä»œæéć
Źćž |
äœäžșć
ç«è°èćçäžćč¶çŻććç©
|
|
US11752131B2
(en)
|
2016-02-19 |
2023-09-12 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and pharmaceutical compositions for the treatment of obesity
|
|
CN112898309A
(zh)
*
|
2016-02-19 |
2021-06-04 |
æŁć€§ć€©æŽèŻäžéćąèĄä»œæéć
Źćž |
äœäžșć
ç«è°èćçäžćč¶çŻććç©
|
|
WO2017149469A1
(en)
|
2016-03-03 |
2017-09-08 |
Emcure Pharmaceuticals Limited |
Heterocyclic compounds useful as ido and/or tdo modulators
|
|
KR20230038311A
(ko)
|
2016-03-04 |
2023-03-17 |
ëžëŠŹì€íš-ë§ìŽìŽì€ ì€í
컎íŒë |
í-cd73 íìČŽìì ìĄ°í© ìëČ
|
|
CN105732643A
(zh)
*
|
2016-04-18 |
2016-07-06 |
èć·ć€§ćŠ |
äžç§ć¶èç©ăć
¶ć¶ć€æčæłććšć¶ć€idoé
¶æć¶ććéçŸäœæçèŻç©äžçćșçš
|
|
US12297266B2
(en)
|
2016-04-18 |
2025-05-13 |
Celldex Therapeutics, Inc. |
Agonistic antibodies that bind human CD40 and uses thereof
|
|
CN107312005B
(zh)
*
|
2016-04-27 |
2021-12-17 |
äžæ”·çż°æŁźçç©ć»èŻç§ææéć
Źćž |
ć
·æido/tdoæć¶æŽ»æ§ççš ććȘćèĄçç©ćć
¶ć¶ć€æčæłććșçš
|
|
JP2019516681A
(ja)
|
2016-05-04 |
2019-06-20 |
ăăȘăčăă«âăă€ă€ăŒăș ăčăŻă€ă ă«ăłăăăŒïŒąïœïœïœïœïœïœâïŒïœïœ
ïœïœ ïŒłïœïœïœïœïœ ïŒŁïœïœïœïœïœïœ |
ă€ăłăăŒă«ăąăăłïŒïŒïŒâăžăȘăă·ăČăăŒăŒé»ćźłć€ăăăłăăźäœżçšæčæł
|
|
US10696648B2
(en)
|
2016-05-04 |
2020-06-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
CN109414420A
(zh)
|
2016-05-04 |
2019-03-01 |
çŸæ¶çŸæœèŽ”ćźć
Źćž |
ćČćèș2,3-ćć æ°§é
¶çæć¶ććć
¶äœżçšæčæł
|
|
JP2019516682A
(ja)
|
2016-05-04 |
2019-06-20 |
ăăȘăčăă«âăă€ă€ăŒăș ăčăŻă€ă ă«ăłăăăŒïŒąïœïœïœïœïœïœâïŒïœïœ
ïœïœ ïŒłïœïœïœïœïœ ïŒŁïœïœïœïœïœïœ |
ă€ăłăăŒă«ăąăăłïŒïŒïŒâăžăȘăă·ăČăăŒăŒé»ćźłć€ăăăłăăźäœżçšæčæł
|
|
US11066383B2
(en)
|
2016-05-04 |
2021-07-20 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
EP3454862B1
(en)
|
2016-05-10 |
2024-09-11 |
C4 Therapeutics, Inc. |
Spirocyclic degronimers for target protein degradation
|
|
EP4491236A3
(en)
|
2016-05-10 |
2025-04-02 |
C4 Therapeutics, Inc. |
Heterocyclic degronimers for target protein degradation
|
|
CN109790143A
(zh)
|
2016-05-10 |
2019-05-21 |
C4ć»èŻć
Źćž |
çšäșé¶èçœéè§Łçèșèżæ„çc3-æäșé
°äșèșéè§Łćłćźćäœ
|
|
CN109641874A
(zh)
|
2016-05-10 |
2019-04-16 |
C4ć»èŻć
Źćž |
çšäșé¶èçœéè§Łçc3-çąłèżæ„çæäșé
°äșèșéè§Łćłćźćäœ
|
|
CN105902542A
(zh)
*
|
2016-05-16 |
2016-08-31 |
ćŒ éł |
äžç§ć¶èç©ćšć¶ć€æČ»çćżèĄçźĄçŸç
èŻç©äžçćșçš
|
|
WO2017198159A1
(zh)
*
|
2016-05-16 |
2017-11-23 |
éČćć¶èŻéćąèĄä»œæéć
Źćž |
㫿Ą„çŻçćȘćèĄçç©
|
|
CN107383012B
(zh)
*
|
2016-05-16 |
2021-09-28 |
éČćć¶èŻéćąèĄä»œæéć
Źćž |
ć«äșçŻçćȘćéèĄçç©
|
|
CN107556316B
(zh)
*
|
2016-06-30 |
2021-11-12 |
éČćć¶èŻéćąèĄä»œæéć
Źćž |
㫿Ą„çŻçćȘćèĄçç©
|
|
CN106957318B
(zh)
*
|
2016-05-19 |
2019-12-10 |
äžćœç§ćŠéąäžæ”·ææșććŠç ç©¶æ |
çš ćć€çŻćČććććç©ăć
¶ć¶ć€æčæłăèŻç©ç»ćç©ććșçš
|
|
EP3439666A4
(en)
|
2016-05-20 |
2019-12-11 |
The University of Chicago |
NANOPARTICLES FOR CHEMOTHERAPY, TARGETED THERAPY, PHOTODYNAMIC THERAPY, IMMUNOTHERAPY AND ALL COMBINATIONS THEREOF
|
|
AR108586A1
(es)
*
|
2016-06-10 |
2018-09-05 |
Lilly Co Eli |
Compuestos de 2,3-dihidro-1h-indol
|
|
CN107488179B
(zh)
*
|
2016-06-11 |
2024-06-07 |
éČćć¶èŻéćąèĄä»œæéć
Źćž |
㫿Ą„çŻçćȘćéèĄçç©
|
|
CN107556315B
(zh)
*
|
2016-06-30 |
2021-08-31 |
éČćć¶èŻéćąèĄä»œæéć
Źćž |
ć«ćć
çŻçćȘćèĄçç©
|
|
MY200602A
(en)
|
2016-07-14 |
2024-01-04 |
Bristol Myers Squibb Co |
Antibodies against tim3 and uses thereof
|
|
WO2018017633A1
(en)
|
2016-07-21 |
2018-01-25 |
Bristol-Myers Squibb Company |
TGF Beta RECEPTOR ANTAGONISTS
|
|
CN107663159A
(zh)
*
|
2016-07-29 |
2018-02-06 |
äžæ”·èżȘèŻșć»èŻç§ææéć
Źćž |
ć€çŻććç©ăć
¶èŻç©ç»ćç©ććșçš
|
|
WO2018028491A1
(zh)
*
|
2016-08-09 |
2018-02-15 |
èć·ćœćĄć»èŻç§ææéć
Źćž |
ćČćèș2ïŒ3-ćć æ°§é
¶æć¶ććć
¶ćšèŻćŠäžççšé
|
|
WO2018039518A1
(en)
|
2016-08-26 |
2018-03-01 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
CN107383024B
(zh)
*
|
2016-09-12 |
2018-06-08 |
ćčżć·ćż
èŽçčć»èŻææŻæéć
Źćž |
ć«ćȘćçš ćäžçŻç±»ććç©ćć
¶ćșçš
|
|
TW201815766A
(zh)
|
2016-09-22 |
2018-05-01 |
çŸćæźé·èŸèŻć
Źćž |
çšæŒïœïœïœćïœïœïœèȘżçŻäčććç©ćæčæłä»„ćć
¶é©æç
|
|
EP3515914A4
(en)
|
2016-09-24 |
2020-04-15 |
BeiGene, Ltd. |
INNOVATIVE 5- OR 8-SUBSTITUTED IMIDAZO [1,5-A] PYRIDINE AS SELECTIVE INHIBITORS OF INDOLEAMINE AND / OR TRYPTOPHANE-2,3-DIOXYGENASES
|
|
BR112019006652A2
(pt)
|
2016-10-13 |
2019-07-02 |
Juno Therapeutics Inc |
métodos e composiçÔes para imunoterapia envolvendo moduladores da via metabólica do triptofano
|
|
TW201815793A
(zh)
*
|
2016-10-21 |
2018-05-01 |
æ±èæçé«è„èĄä»œæéć
Źćž |
äžçšźćȘć䞊ç°ćČćéĄèĄçç©çééąéčŒçç”æ¶ćœąćŒćć
¶èŁœćæčæł
|
|
WO2018072743A1
(zh)
*
|
2016-10-21 |
2018-04-26 |
èć·çèżȘäșçç©ć»èŻæéć
Źćž |
Pd-1æäœäžidoæć¶ćèććšć¶ć€æèżç€çèŻç©äžççšé
|
|
EP3535243B1
(en)
|
2016-11-04 |
2021-12-15 |
Auckland Uniservices Limited |
Substituted 9h-xanthen-9-one, 9h-thioxanthen-9-one and acridin-9(10h)-one derivatives and related compounds csf-1r inhibitors for the treatment of cancer
|
|
CN106474468B
(zh)
*
|
2016-11-23 |
2020-03-27 |
äžćœć»ćŠç§ćŠéąć»ćŠçç©ćŠç ç©¶æ |
äžç§ć€ćäœćăć«èŻ„ć€ćäœćçç«èćç«èçć¶ć€æčæł
|
|
WO2018106579A1
(en)
*
|
2016-12-06 |
2018-06-14 |
Albert Einstein College Of Medicine, Inc. |
Drug targeting of human indoleamine 2,3-dioxygenase
|
|
CN108203438B
(zh)
*
|
2016-12-20 |
2021-09-28 |
æ·±ćłćŸźèŻçç©ç§æèĄä»œæéć
Źćž |
ć
·æćČćèș2,3-ćć æ°§é
¶æć¶æŽ»æ§ççš ććȘćććç©
|
|
SMT202100573T1
(it)
|
2016-12-22 |
2021-11-12 |
Calithera Biosciences Inc |
Composizioni e metodi per l'inibizione dell'attivita' dell'arginasi
|
|
CN108239091B
(zh)
*
|
2016-12-26 |
2021-08-13 |
äžćœć»ćŠç§ćŠéąèŻç©ç ç©¶æ |
1-çŻć·±ćș-2-(5H-ćȘć[5,1-a]ćŒćČć)äčćș-1-é
źçæć
|
|
US10961239B2
(en)
|
2017-01-05 |
2021-03-30 |
Bristol-Myers Squibb Company |
TGF beta receptor antagonists
|
|
JP2020506895A
(ja)
|
2017-01-17 |
2020-03-05 |
ăăŒă ăȘă ăŹăžă§ăłă, ă¶ ăŠăăăŒă·ă㣠ăȘă ăăă”ăč ă·ăčăă Board Of Regents, The University Of Texas System |
ă€ăłăăŒă«ăąăăłïŒïŒïŒâăžăȘăă·ăČăăŒăŒăăăłïŒăŸăăŻăăȘăăăăĄăłăžăȘăă·ăČăăŒăŒăźé»ćźłć€ăšăăŠæçšăȘććç©
|
|
WO2018175954A1
(en)
|
2017-03-23 |
2018-09-27 |
F. Hoffmann-La Roche Ag |
Synthesis of imidazo[5,1-a]isoindole derivative useful as ido inhibitors
|
|
CA3057687A1
(en)
|
2017-03-31 |
2018-10-04 |
Five Prime Therapeutics, Inc. |
Combination therapy for cancer using anti-gitr antibodies
|
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
çŸććż
æČ»ćŠ„çŸé
ćČè°·æŻć
Źćž |
æicosäżæćæé«ćć
¶çšé
|
|
WO2018195397A2
(en)
|
2017-04-21 |
2018-10-25 |
Kyn Therapeutics |
Indole ahr inhibitors and uses thereof
|
|
WO2018201014A1
(en)
|
2017-04-28 |
2018-11-01 |
Five Prime Therapeutics, Inc. |
Methods of treatment with cd80 extracellular domain polypeptides
|
|
US11066392B2
(en)
|
2017-05-12 |
2021-07-20 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
CN107176956B
(zh)
*
|
2017-05-31 |
2019-11-12 |
æéœæ”·ćéèŻäžæéć
Źćž |
äžç§idoæć¶ćććç©ăèŻçšç»ćç©ăçšé
|
|
EP4717317A2
(en)
|
2017-06-20 |
2026-04-01 |
C4 Therapeutics, Inc. |
N/o-linked degrons and degronimers for protein degradation
|
|
JP7301757B2
(ja)
|
2017-06-26 |
2023-07-03 |
ăă€ăčăŻă«ăąăŒă«ăăŁăŒă»ăȘăăăă |
æ€ćșćŻèœéšćăæă€äșç°ćŒăăăăăȘăŹăłăăăăłăăźäœżçš
|
|
US11827639B2
(en)
|
2017-06-28 |
2023-11-28 |
Genentech, Inc. |
TDO2 and IDO1 inhibitors
|
|
EP3645533B1
(en)
|
2017-06-28 |
2025-03-26 |
Genentech, Inc. |
Tdo2 and ido1 inhibitors
|
|
US11236049B2
(en)
|
2017-06-30 |
2022-02-01 |
Bristol-Myers Squibb Company |
Amorphous and crystalline forms of IDO inhibitors
|
|
KR102709265B1
(ko)
|
2017-07-28 |
2024-09-23 |
ëžëŠŹì€íš-ë§ìŽìŽì€ ì€í
컎íŒë |
íìì ëĄìì ìíŽëŠ ëëŽíŽë ì€í°ë
|
|
EP3638367A4
(en)
|
2017-08-02 |
2021-07-21 |
The University of Chicago |
NANOMETRIC ORGANOMETALLIC AND NANOPLAQUE ORGANOMETALLIC LAYERS FOR X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, RADIODYNAMIC THERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION OF THESE
|
|
CN111183147B
(zh)
|
2017-08-04 |
2024-07-05 |
ææŻç§ææŻćŒćæéć
Źćž |
Cd137çčćŒæ§çćçŻèœé
äœ
|
|
TW201910336A
(zh)
*
|
2017-08-08 |
2019-03-16 |
性éžćæ±èæçé«è„èĄä»œæéć
Źćž |
äžçšźćȘććč¶ç°ćČćéĄèĄçç©çèŁœćæčæł
|
|
CN109384791B
(zh)
*
|
2017-08-09 |
2020-09-11 |
æ±èæçć»èŻèĄä»œæéć
Źćž |
äžç§ćȘććč¶ćŒćČćç±»èĄçç©æžžçŠ»çą±çæ¶ććć
¶ć¶ć€æčæł
|
|
WO2019036657A1
(en)
|
2017-08-17 |
2019-02-21 |
Kyn Therapeutics |
AHR INHIBITORS AND USES THEREOF
|
|
CA3072989A1
(en)
|
2017-08-17 |
2019-02-21 |
Idorsia Pharmaceuticals Ltd |
Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
|
|
CN111263763B
(zh)
*
|
2017-08-18 |
2021-02-19 |
æŁć€§ć€©æŽèŻäžéćąèĄä»œæéć
Źćž |
äžç§äžćč¶çŻććç©çç»æ¶
|
|
JP6934562B2
(ja)
*
|
2017-08-22 |
2021-09-15 |
ăźăȘăąăŒă ă”ă€ăšăłă·ăŒășïŒ ă€ăłăłăŒăăŹă€ăăă |
æČ»ççšè€çŽ ç°ćŒććç©
|
|
US10947263B2
(en)
|
2017-08-31 |
2021-03-16 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
|
ES2904317T3
(es)
|
2017-08-31 |
2022-04-04 |
Bristol Myers Squibb Co |
DinucleĂłtidos cĂclicos como agentes anticancerosos
|
|
US11667663B2
(en)
|
2017-08-31 |
2023-06-06 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
|
CN107501272B
(zh)
*
|
2017-09-05 |
2020-03-31 |
äžćœèŻç§ć€§ćŠ |
ćȘććč¶ćŒćČćç±»ido1æć¶ćăć
¶ć¶ć€æčæłććșçš
|
|
WO2019055786A1
(en)
|
2017-09-14 |
2019-03-21 |
Lankenau Institute For Medical Research |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
|
|
WO2019060693A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES THEREOF
|
|
MX2020003190A
(es)
|
2017-09-22 |
2020-11-11 |
Kymera Therapeutics Inc |
Degradadores de proteinas y usos de los mismos.
|
|
US11203592B2
(en)
|
2017-10-09 |
2021-12-21 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
US11649212B2
(en)
|
2017-10-09 |
2023-05-16 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
US11660311B2
(en)
|
2017-10-10 |
2023-05-30 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
|
EP3694552A1
(en)
|
2017-10-10 |
2020-08-19 |
Tilos Therapeutics, Inc. |
Anti-lap antibodies and uses thereof
|
|
US11427610B2
(en)
|
2017-10-16 |
2022-08-30 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
|
WO2019078246A1
(ja)
|
2017-10-19 |
2019-04-25 |
äžèŹç€ŸćŁæłäșșăăĄă«ăăăŹăŒăăăžă§ăŻăæŻæŽæ©æ§ |
ïœïœïŒïœïœïœé»ćźłć€
|
|
CN111542544A
(zh)
|
2017-11-01 |
2020-08-14 |
çŸæ¶çŸæœèŽ”ćźć
Źćž |
çšäșæČ»ççççć
ç«ćșæżæ§æżćšæ§æäœ
|
|
JP7167146B2
(ja)
|
2017-11-06 |
2022-11-08 |
ăăȘăčăă«ïŒăă€ă€ăŒăș ăčăŻă€ă ă«ăłăăăŒ |
ïœïœïŒé»ćźłć€ăšăăŠæçšăȘă€ăœăă©ăăłććç©
|
|
CN111386114A
(zh)
|
2017-11-25 |
2020-07-07 |
çŸæ”ç„ć·æéć
Źćž |
äœäžșćČćèș2,3-ćć æ°§é
¶çéæ©æ§æć¶ćçæ°éąèŻćč¶ćȘć
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
CN111788227B
(zh)
|
2017-12-27 |
2025-02-25 |
çŸæ¶çŸæœèŽ”ćźć
Źćž |
æcd40æäœćć
¶çšé
|
|
US11447449B2
(en)
|
2018-01-05 |
2022-09-20 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
WO2019140387A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
|
KR20250078626A
(ko)
|
2018-01-12 |
2025-06-02 |
ëžëŠŹì€íš-ë§ìŽìŽì€ ì€í
컎íŒë |
Tim3ì ëí íìČŽ ë° ê·žì ì©ë
|
|
WO2019140380A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
EP3740493B1
(en)
|
2018-01-15 |
2021-12-01 |
Idorsia Pharmaceuticals Ltd |
Inhibteurs de l'indoleamine 2,3-dioxygénase et/ou du tryptophane dioxygénase
|
|
WO2019141095A1
(zh)
*
|
2018-01-19 |
2019-07-25 |
ćć·ç§äŒŠćæł°çç©ć»èŻèĄä»œæéć
Źćž |
èç±»ćèç±»èĄçç©ăć
¶ć¶ć€æčæłćć
¶ćšć»èŻäžçćșçš
|
|
EP3746071A4
(en)
|
2018-01-29 |
2021-09-01 |
Merck Patent GmbH |
GCN2 INHIBITORS AND THEIR USES
|
|
KR20200116481A
(ko)
|
2018-01-29 |
2020-10-12 |
ë©ë„ŽíŹ íí
íž êČì ëČ í |
Gcn2 ì”ì ì ë° ìŽì ì©ë
|
|
US10519187B2
(en)
|
2018-02-13 |
2019-12-31 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
|
JP2021514953A
(ja)
|
2018-02-23 |
2021-06-17 |
ăă€ăčăŻă«ăăŻăčă»ăȘăăăă |
ć€éäœäșç°ćŒăăăăăȘăŹăłă
|
|
KR20200130362A
(ko)
|
2018-03-08 |
2020-11-18 |
ëžëŠŹì€íš-ë§ìŽìŽì€ ì€í
컎íŒë |
íìì ëĄìì ìíŽëŠ ëëŽíŽë ì€í°ë
|
|
AU2019239952A1
(en)
|
2018-03-20 |
2020-10-08 |
Plexxikon Inc. |
Compounds and methods for IDO and TDO modulation, and indications therefor
|
|
BR112020019083A2
(pt)
|
2018-03-21 |
2020-12-29 |
Five Prime Therapeutics, Inc. |
Anticorpos, åcido nucleico, composiçÔes, célula e métodos para preparar um anticorpo, para tratar cùncer, para tratar uma doença infecciosa, para tratar uma inflamação, para a identificação de um anticorpo, para melhorar a eficåcia antitumoral de um anticorpo, para melhorar a farmacocinética de um anticorpo, para selecionar um anticorpo, para melhorar a eficåcia de anticorpos, para isolar anticorpos, para detectar vista em uma amostra e para tratar cùncer
|
|
PE20210665A1
(es)
|
2018-03-23 |
2021-03-31 |
Bristol Myers Squibb Co |
Anticuerpos contra mica y/o micb y sus usos
|
|
US20210147570A1
(en)
|
2018-04-12 |
2021-05-20 |
Bristol-Myers Squibb Company |
Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody
|
|
US10973834B2
(en)
|
2018-04-16 |
2021-04-13 |
Arrys Therapeutics, Inc. |
EP4 inhibitors and use thereof
|
|
US12037323B2
(en)
|
2018-05-03 |
2024-07-16 |
Bristol-Myers Squibb Company |
Uracil derivatives as Mer-AXL inhibitors
|
|
IL279489B2
(en)
|
2018-06-22 |
2025-10-01 |
Bicycletx Ltd |
Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate
|
|
PT3814347T
(pt)
|
2018-06-27 |
2023-07-18 |
Bristol Myers Squibb Co |
Compostos de naftiridinona Ășteis como ativadores de cĂ©lulas t
|
|
CN112654621B
(zh)
|
2018-06-27 |
2024-05-14 |
çŸæ¶çŸæœèŽ”ćźć
Źćž |
ćŻäœäžștç»è掻ććçç»ć代èć¶é
źććç©
|
|
WO2020010227A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
|
TW202428604A
(zh)
|
2018-07-09 |
2024-07-16 |
çŸćæçæČ»çæéć
Źćž |
ç”ćèłilt4çæé«
|
|
BR112021000303A2
(pt)
|
2018-07-11 |
2021-04-13 |
Five Prime Therapeutics, Inc. |
Anticorpos que se ligam a vista em ph ĂĄcido
|
|
WO2020018670A1
(en)
|
2018-07-17 |
2020-01-23 |
Board Of Regents, The University Of Texas System |
Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
|
|
US12059420B2
(en)
|
2018-07-23 |
2024-08-13 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
WO2020023356A1
(en)
|
2018-07-23 |
2020-01-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
US10959986B2
(en)
|
2018-08-29 |
2021-03-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
US11253525B2
(en)
|
2018-08-29 |
2022-02-22 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
US12030875B2
(en)
|
2018-09-07 |
2024-07-09 |
PIC Therapeutics, Inc. |
EIF4E inhibitors and uses thereof
|
|
KR102833434B1
(ko)
|
2018-09-27 |
2025-07-15 |
ìì ìč©ì€íŹëа ë°ìŽì€ìŹìŽìžì€ ìšì€., ìí°ë. |
ìžëìëŻŒ-2,3-ëì„ìêČëìì ì”ì íì±ì ê°ë íŽë늰 ì ëìČŽ
|
|
EP3863722A2
(en)
|
2018-10-10 |
2021-08-18 |
Tilos Theapeutics, Inc. |
Anti-lap antibody variants and uses thereof
|
|
US11274150B2
(en)
|
2018-11-16 |
2022-03-15 |
Bristol-Myers Squibb Company |
Anti-human natural killer cell inhibitory receptor group 2A protein (NKG2A) antibodies
|
|
JP7623943B2
(ja)
|
2018-11-30 |
2025-01-29 |
ă«ă€ăĄă© ă»ă©ăă„ăŒăăŁăŻăčïŒ ă€ăłăłăŒăăŹă€ăăă |
ïœïœïœćè§Łć€ăăăłăăăăźäœżçš
|
|
GB201820325D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for psma
|
|
GB201820288D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicycle Tx Ltd |
Bicycle peptide ligaands specific for MT1-MMP
|
|
GB201820295D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for MT1-MMP
|
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
|
CN120698983A
(zh)
|
2018-12-20 |
2025-09-26 |
C4ć»èŻć
Źćž |
é¶ćèçœéè§Ł
|
|
US12551567B2
(en)
|
2018-12-21 |
2026-02-17 |
Bicyclerd Limited |
Bicyclic peptide ligands specific for PD-L1
|
|
JP2022514618A
(ja)
|
2018-12-21 |
2022-02-14 |
ăă€ăčăŻă«ăăŻăčă»ăȘăăăă |
ïœïŒïœïŒă«çčç°çăȘäșç°ćŒăăăăăȘăŹăłă
|
|
CN120131907A
(zh)
|
2019-03-19 |
2025-06-13 |
çŠć°ćžäŒŻäŒŠç§äșșèżç€ç ç©¶ćșéäŒ |
éçšOmomycćç»ćPD-1æCTLA-4çæäœæČ»ççççèćçæł
|
|
US20220184222A1
(en)
|
2019-04-02 |
2022-06-16 |
Bicycletx Limited |
Bicycle toxin conjugates and uses thereof
|
|
TWI875749B
(zh)
|
2019-04-05 |
2025-03-11 |
çŸćć±éș„æé«çć
Źćž |
Statéè§Łććć
¶çšé
|
|
WO2020231713A1
(en)
|
2019-05-13 |
2020-11-19 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
|
WO2020231766A1
(en)
|
2019-05-13 |
2020-11-19 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
|
WO2020243423A1
(en)
|
2019-05-31 |
2020-12-03 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
WO2020251972A1
(en)
|
2019-06-10 |
2020-12-17 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
BR112021026517A2
(pt)
|
2019-06-28 |
2022-05-10 |
Kymera Therapeutics Inc |
Degradadores de irak e usos dos mesmos
|
|
JP2022540146A
(ja)
|
2019-07-11 |
2022-09-14 |
ă€ăăŒă·ăą ăăĄăŒăă·ă„ăŒăăŁă«ă«ăș ăȘăăăă |
ă€ăłăăŒă«ăąăăł ïŒïŒïŒïŒăžăȘăă·ăČăăŒăŒćăłïŒćăŻăăȘăăăăĄăł ïŒïŒïŒïŒăžăȘăă·ăČăăŒăŒăźé»ćźłć€
|
|
WO2021011868A1
(en)
|
2019-07-17 |
2021-01-21 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
TWI860386B
(zh)
|
2019-07-30 |
2024-11-01 |
è±ćæè„żćŻæł°ć
æŻæéć
Źćž |
ç°èłȘéç°èœè€ćç©
|
|
US20220306630A1
(en)
|
2019-08-06 |
2022-09-29 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
|
AR119821A1
(es)
|
2019-08-28 |
2022-01-12 |
Bristol Myers Squibb Co |
Compuestos de piridopirimidinonilo sustituidos Ăștiles como activadores de cĂ©lulas t
|
|
CN114945366B
(zh)
|
2019-09-13 |
2025-01-07 |
æäŒŻćŁ«èšéĄżć
Źćž |
Hpk1æźæććć
¶çšé
|
|
EP4031575A1
(en)
|
2019-09-19 |
2022-07-27 |
Bristol-Myers Squibb Company |
Antibodies binding to vista at acidic ph
|
|
AU2020387392B2
(en)
|
2019-11-19 |
2025-09-11 |
Bristol-Myers Squibb Company |
Compounds useful as inhibitors of Helios protein
|
|
PT4065582T
(pt)
|
2019-11-26 |
2025-05-22 |
Ikena Oncology Inc |
Derivados polimórficos do carbazol e utilizaçÔes dos mesmos
|
|
WO2021108288A1
(en)
|
2019-11-26 |
2021-06-03 |
Bristol-Myers Squibb Company |
Salts/cocrystals of (r)-n-(4-chlorophenyl)-2-((1s,4s)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide
|
|
US12551564B2
(en)
|
2019-12-10 |
2026-02-17 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
CN111333653A
(zh)
*
|
2019-12-16 |
2020-06-26 |
ć±±äžć€§ćŠ |
äžç§icdèŻ±ćŻŒć-idoæć¶ćçŒćç©ćć¶ć€æčæłäžćșçš
|
|
WO2021127283A2
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
WO2021127190A1
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
IL294273A
(en)
|
2019-12-23 |
2022-08-01 |
Bristol Myers Squibb Co |
Substituted heteroaryl compounds are useful as t-cell activators
|
|
BR112022012410A2
(pt)
|
2019-12-23 |
2022-08-30 |
Kymera Therapeutics Inc |
Degradadores smarca e usos dos mesmos
|
|
AR120823A1
(es)
|
2019-12-23 |
2022-03-23 |
Bristol Myers Squibb Co |
Compuestos bicĂclicos sustituidos Ăștiles como activadores de cĂ©lulas t
|
|
KR20220119456A
(ko)
|
2019-12-23 |
2022-08-29 |
ëžëŠŹì€íš-ë§ìŽìŽì€ ì€í
컎íŒë |
T ìžíŹ íì±íì ëĄì ì ì©í ìčíë íŽë늏ë
žë íŒíëŒì§ íí©ëŹŒ
|
|
EP4081522A1
(en)
|
2019-12-23 |
2022-11-02 |
Bristol-Myers Squibb Company |
Substituted piperazine derivatives useful as t cell activators
|
|
CN114846007B
(zh)
|
2019-12-23 |
2024-11-22 |
çŸæ¶çŸæœèŽ”ćźć
Źćž |
ćŻçšäœtç»èæżæŽ»ćçç»ć代çćčćććșććç©
|
|
BR112022013424A2
(pt)
|
2020-01-06 |
2022-12-13 |
Hifibio Hk Ltd |
Anticorpo anti-tnfr2 e seus usos
|
|
KR20220123105A
(ko)
|
2020-01-07 |
2022-09-05 |
íìŽíìŽë°ìŽì€ (ììŽìčìŒìŽ) 늏믞í°ë |
í-ê°ë íŽ-9 íìČŽ ë° ê·žêČì ì©ë
|
|
EP4090663A1
(en)
|
2020-01-15 |
2022-11-23 |
Blueprint Medicines Corporation |
Map4k1 inhibitors
|
|
AU2021230289A1
(en)
|
2020-03-03 |
2022-09-29 |
PIC Therapeutics, Inc. |
eIF4E inhibitors and uses thereof
|
|
WO2021183428A1
(en)
|
2020-03-09 |
2021-09-16 |
Bristol-Myers Squibb Company |
Antibodies to cd40 with enhanced agonist activity
|
|
US12528785B2
(en)
|
2020-03-19 |
2026-01-20 |
Kymera Therapeutics, Inc. |
MDM2 degraders and uses thereof
|
|
TW202140441A
(zh)
|
2020-03-23 |
2021-11-01 |
çŸććż
æČ»ćŠ„çŸé
ćČè°·æŻć
Źćž |
ç¶ć代äčćŽæ°§ćșç°ćČććććç©
|
|
EP4132971A1
(en)
|
2020-04-09 |
2023-02-15 |
Merck Sharp & Dohme LLC |
Affinity matured anti-lap antibodies and uses thereof
|
|
WO2021231732A1
(en)
|
2020-05-15 |
2021-11-18 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
çŸćć±éș„æé«çć
Źćž |
Irakéè§Łćäčç”æ¶ć
|
|
WO2021247897A1
(en)
|
2020-06-03 |
2021-12-09 |
Kymera Therapeutics, Inc. |
Deuterated irak degraders and uses thereof
|
|
CN111803635B
(zh)
*
|
2020-06-17 |
2023-03-14 |
äžćœć»ćŠç§ćŠéąćșçĄć»ćŠç ç©¶æ |
ć°ććæć¶ććšæČ»çćŒćžéç
æŻæ§èșçäžçćșçš
|
|
WO2021258010A1
(en)
|
2020-06-19 |
2021-12-23 |
Gossamer Bio Services, Inc. |
Oxime compounds useful as t cell activators
|
|
US11839659B2
(en)
|
2020-07-02 |
2023-12-12 |
Northwestern University |
Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein
|
|
US11857535B2
(en)
|
2020-07-30 |
2024-01-02 |
Kymera Therapeutics, Inc. |
Methods of treating mutant lymphomas
|
|
IL300248A
(en)
|
2020-08-03 |
2023-03-01 |
Bicycletx Ltd |
peptide-based linkers
|
|
CN116724051A
(zh)
|
2020-08-10 |
2023-09-08 |
äžæ”·ćŻ»çŸäŒçç©ææŻæéć
Źćž |
çšäșéèżé¶ćigsf8æ„æČ»çèȘèș«ć
ç«æ§çŸç
ćçççç»ćç©ćæčæł
|
|
WO2022038158A1
(en)
|
2020-08-17 |
2022-02-24 |
Bicycletx Limited |
Bicycle conjugates specific for nectin-4 and uses thereof
|
|
CA3198456A1
(en)
|
2020-10-14 |
2022-04-21 |
Five Prime Therapeutics, Inc. |
Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
|
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
EP4255895A1
(en)
|
2020-12-02 |
2023-10-11 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
EP4259144A4
(en)
|
2020-12-09 |
2025-08-20 |
Kymera Therapeutics Inc |
SMARCA DEGRADING AGENTS AND THEIR USES
|
|
EP4262986A1
(en)
|
2020-12-16 |
2023-10-25 |
Gossamer Bio Services, Inc. |
Compounds useful as t cell activators
|
|
PH12023500015A1
(en)
|
2020-12-30 |
2024-03-11 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
US20250186539A2
(en)
|
2021-01-11 |
2025-06-12 |
Bicycletx Limited |
Methods for treating cancer
|
|
EP4288427A1
(en)
|
2021-02-02 |
2023-12-13 |
Liminal Biosciences Limited |
Gpr84 antagonists and uses thereof
|
|
JP2024506858A
(ja)
|
2021-02-02 |
2024-02-15 |
ăȘăăă«ă»ăă€ăȘă”ă€ăšăłă·ăŒășă»ăȘăăăă |
ïœïœïŒïŒăąăłăżăŽăăčăăăăłăăźäœżçš
|
|
WO2022169921A1
(en)
|
2021-02-04 |
2022-08-11 |
Bristol-Myers Squibb Company |
Benzofuran compounds as sting agonists
|
|
JP7821808B2
(ja)
|
2021-02-12 |
2026-02-27 |
ăšăă»ăăăăłïŒă©ă»ăă·ă„ă»ăąăŻăă§ăłăČăŒă«ă·ăŁăă |
ăăăźæČ»çăźăăăźäșç°ćŒăăă©ăăăăąăŒăăłèȘć°äœ
|
|
CN117120090A
(zh)
|
2021-02-12 |
2023-11-24 |
æäŒŻćŁ«èšéĄżć
Źćž |
Hpk1æźæććć
¶çšé
|
|
CN116867494A
(zh)
|
2021-02-15 |
2023-10-10 |
ćŻéșŠæć»çć
Źćž |
Irak4éè§Łććć
¶çšé
|
|
WO2022174268A1
(en)
|
2021-02-15 |
2022-08-18 |
Kymera Therapeutics, Inc. |
Irak4 degraders and uses thereof
|
|
WO2022184930A2
(en)
|
2021-03-05 |
2022-09-09 |
UniversitÀt Basel |
Compositions for the treatment of ebv associated diseases or conditions
|
|
EP4052705A1
(en)
|
2021-03-05 |
2022-09-07 |
UniversitÀt Basel Vizerektorat Forschung |
Compositions for the treatment of ebv associated diseases or conditions
|
|
EP4301756A4
(en)
|
2021-03-05 |
2025-02-26 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
|
JP2024510176A
(ja)
|
2021-03-08 |
2024-03-06 |
ăă«ăŒăăȘăłă ăĄăăŁă·ăłăș ăłăŒăăŹă€ă·ă§ăł |
ïŒïœïœïŒïœïŒé»ćźłć€
|
|
US11918582B2
(en)
|
2021-03-15 |
2024-03-05 |
Rapt Therapeutics, Inc. |
Pyrazole pyrimidine compounds and uses thereof
|
|
WO2022213062A1
(en)
|
2021-03-29 |
2022-10-06 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
|
JP2024514530A
(ja)
|
2021-04-02 |
2024-04-02 |
ă¶ ăȘăŒăžă§ăłă ăȘă ă¶ ăŠăăăŒă·ă㣠ăȘă ă«ăȘăă©ă«ăăą |
ćæćïœïœïœïœïŒă«ćŻŸăăæäœăăăłăăźäœżçš
|
|
BR112023020410A2
(pt)
|
2021-04-05 |
2023-11-28 |
Bristol Myers Squibb Co |
Compostos de oxoisoindolina substituĂda por piridinila para tratamento de cĂąncer
|
|
BR112023020077A2
(pt)
|
2021-04-06 |
2023-11-14 |
Bristol Myers Squibb Co |
Compostos de oxoisoindolina substituĂda por piridinila
|
|
AU2022256074A1
(en)
|
2021-04-09 |
2023-11-02 |
Nimbus Clio, Inc. |
Cbl-b modulators and uses thereof
|
|
JP2024514879A
(ja)
|
2021-04-16 |
2024-04-03 |
ă€ă±ă ăȘăłăłăăžăŒïŒ ă€ăłăłăŒăăŹă€ăăă |
ïŒïœ
ïœé»ćźłć€ćăłăăźäœżçš
|
|
AU2022271290A1
(en)
|
2021-05-07 |
2023-11-23 |
Kymera Therapeutics, Inc. |
Cdk2 degraders and uses thereof
|
|
KR20240083168A
(ko)
|
2021-07-14 |
2024-06-11 |
ëžëŁšíëŠ°íž ë©ëì ìŠ ìœíŹë ìŽì
|
Map4k1 ì íŽì ëĄìì í€í
ëĄìŹìŽíŽ íí©ëŹŒ
|
|
US20240336630A1
(en)
|
2021-07-15 |
2024-10-10 |
Blueprint Medicines Corporation |
Map4k1 inhibitors
|
|
US12157732B2
(en)
|
2021-08-25 |
2024-12-03 |
PIC Therapeutics, Inc. |
eIF4E inhibitors and uses thereof
|
|
JP2024534127A
(ja)
|
2021-08-25 |
2024-09-18 |
ă㯠ă»ă©ăă„ăŒăăŁăŻăčïŒ ă€ăłăłăŒăăŹă€ăăă |
ïœ
ïŒïŒ„é»ćźłć€ćăłăăźäœżçš
|
|
US12187744B2
(en)
|
2021-10-29 |
2025-01-07 |
Kymera Therapeutics, Inc. |
IRAK4 degraders and synthesis thereof
|
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
WO2023122777A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Oxime derivatives useful as t cell activators
|
|
WO2023122772A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Oxime derivatives useful as t cell activators
|
|
WO2023122778A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Pyridazinone derivatives useful as t cell activators
|
|
EP4472967A4
(en)
|
2022-01-31 |
2026-04-15 |
Kymera Therapeutics Inc |
Iraqi Degradation Agents and Their Uses
|
|
EP4472963A1
(en)
|
2022-02-01 |
2024-12-11 |
Arvinas Operations, Inc. |
Dgk targeting compounds and uses thereof
|
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
|
IL316768A
(en)
|
2022-05-25 |
2025-01-01 |
Ikena Oncology Inc |
MEK inhibitors and their uses
|
|
JP2025527247A
(ja)
|
2022-08-02 |
2025-08-20 |
ăȘăăă«ă»ăă€ăȘă”ă€ăšăłă·ăŒășă»ăȘăăăă |
ăąăȘăŒă«ïŒăăȘăąăŸăȘă«ćăłéąéŁăăïœïœïœïŒïŒăąăłăżăŽăăčăăȘăăłă«ăăăăźäœżçš
|
|
CN120051456A
(zh)
|
2022-08-02 |
2025-05-27 |
é米èŻșçç©ç§ćŠæéć
Źćž |
ć代çćĄć¶é
źgpr84æźæććć
¶çšé
|
|
IL318575A
(en)
|
2022-08-02 |
2025-03-01 |
Liminal Biosciences Ltd |
HETEROARYL CARBOXAMIDE AND GPR84-RELATED ANTAGONISTS AND USES THEREOF
|
|
US20260049068A1
(en)
|
2022-08-08 |
2026-02-19 |
Bristol-Myers Squibb Company |
Substituted Tetrazolyl Compounds Useful as T Cell Activators
|
|
KR20250046310A
(ko)
|
2022-08-09 |
2025-04-02 |
ëžëŠŹì€íš-ë§ìŽìŽì€ ì€í
컎íŒë |
T ìžíŹ íì±íì ëĄì ì ì©í 3êž ìëŻŒ ìčíë ëčìíŽëŠ íí©ëŹŒ
|
|
WO2024033388A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
|
CR20250043A
(es)
|
2022-08-11 |
2025-03-25 |
Hoffmann La Roche |
Derivados bicĂclicos de tetrahidrotiazepina
|
|
WO2024033457A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
|
TW202417001A
(zh)
|
2022-08-11 |
2024-05-01 |
ç棫ć蔫ććæçŸ
èĄä»œć
Źćž |
éç°ćæ°«ććŻèĄçç©
|
|
US20240208961A1
(en)
|
2022-11-22 |
2024-06-27 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
|
CN116143726B
(zh)
*
|
2022-12-02 |
2024-09-06 |
ćčżć·ćžèçć¶èŻæéć
Źćž |
äžç§çŻçŁ·è
șè·æèŽšçć¶ć€æčæł
|
|
WO2024137865A1
(en)
|
2022-12-22 |
2024-06-27 |
Gossamer Bio Services, Inc. |
Compounds useful as t cell activators
|
|
PE20260451A1
(es)
|
2023-05-08 |
2026-02-25 |
Bristol Myers Squibb Co |
Compuestos de feniloxazolona sustituida
|
|
EP4709712A1
(en)
|
2023-05-10 |
2026-03-18 |
Blueprint Medicines Corporation |
Gsk3a inhibitors and methods of use thereof
|
|
AU2024281056A1
(en)
|
2023-05-31 |
2026-01-22 |
Bristol-Myers Squibb Company |
Substituted oxazolone compound for decreasing levels of ikzf1-4 proteins
|
|
EP4724149A1
(en)
|
2023-06-07 |
2026-04-15 |
Bristol-Myers Squibb Company |
Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound
|
|
AU2024314878A1
(en)
|
2023-06-23 |
2026-01-22 |
Bristol-Myers Squibb Company |
Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent
|
|
IL321486A
(en)
|
2023-06-23 |
2025-08-01 |
Kymera Therapeutics Inc |
Iraqi joints and their uses
|
|
WO2025030002A2
(en)
|
2023-08-02 |
2025-02-06 |
Arvinas Operations, Inc. |
Dgk targeting compounds and uses thereof
|
|
TW202525802A
(zh)
|
2023-09-02 |
2025-07-01 |
çŸććż
æČ»ćŠ„çŸé
ćČè°·æŻć
Źćž |
ç¶ć代äčèŻćșæ°§ä»Łăććșćć¶äșé
źććç©
|
|
IL326828A
(en)
|
2023-09-02 |
2026-04-01 |
Bristol Myers Squibb Co |
Piperidine-2,6-dione azatidinyl oxoisoindolinyl substituted compounds
|
|
FI4587429T3
(fi)
|
2023-09-13 |
2026-03-24 |
Bristol Myers Squibb Co |
Substituoituja oksoindolinyylipiperidiini-2,6-dioniyhdisteitÀ
|
|
WO2025096505A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096488A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096490A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096489A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096494A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096487A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
TW202535865A
(zh)
|
2023-10-31 |
2025-09-16 |
çŸććż
æČ»ćŠ„çŸé
ćČè°·æŻć
Źćž |
æłçŽ çčç°æ§ć ć·„èçœé
¶1 (usp1) ććç©
|
|
WO2025226767A1
(en)
|
2024-04-24 |
2025-10-30 |
Bristol-Myers Squibb Company |
Substituted 3-(5-(6-aminopyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds for use in the treatment of cancer
|
|
WO2026035787A1
(en)
|
2024-08-07 |
2026-02-12 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) macrocyles
|
|
WO2026080794A1
(en)
|
2024-10-11 |
2026-04-16 |
Bristol-Myers Squibb Company |
Chemical compounds useful for degrading proteins
|
|
CN119707950A
(zh)
*
|
2024-12-24 |
2025-03-28 |
æ éĄćžćäșŹć€§ćŠéĄć±±ćșçšçç©ææŻç ç©¶æ |
äžç§çšäșć
ç«èçœé¶ćéè§Łçć”ćäœćć
¶ć¶ć€æčæłććșçš
|